Tresiba Cost in North Carolina 2026: Prices, Insurance, Medicaid, and Savings Options

What Is the Cash Price of Tresiba in North Carolina in 2026?

Tresiba's Novo Nordisk wholesale list price in the United States is approximately $510 per month for a standard supply. North Carolina retail pharmacies typically price it near that list figure without insurance, but applying a GoodRx or similar pharmacy discount coupon brings the average NC cash price to roughly $35 per month at major chains. The gap between list and discount price is wide, so always check a discount coupon before paying out of pocket.

Insulin degludec (brand name Tresiba) is a once-daily, long-acting basal insulin approved by the FDA in September 2015 for adults and pediatric patients aged one year and older with type 1 or type 2 diabetes. [1] The drug's ultra-long half-life of approximately 25 hours allows flexible daily injection timing without clinically meaningful changes in glycemic control, a property confirmed in the DEVOTE cardiovascular outcomes trial. [2] Because basal insulin is a chronic, non-negotiable therapy for many people with type 1 diabetes, the price difference between list and cash-pay figures has real monthly consequences.

Pharmacy prices vary by zip code within North Carolina. Urban pharmacies in Charlotte, Raleigh, and Durham tend to have more competitive discount pricing than rural western NC pharmacies, where fewer chains compete. Calling ahead or using the GoodRx or NeedyMeds pharmacy comparison tool takes about three minutes and can save $10 to $40 per fill even within the discount tier. [3]

The FDA's Center for Drug Evaluation and Research maintains the current approved labeling for Tresiba, which lists available concentrations (U-100 and U-200 FlexTouch pens) and the recommended starting dose of 10 units once daily for insulin-naive type 2 patients. [1] Dose titration targets a fasting self-monitored blood glucose of 80 to 130 mg/dL per American Diabetes Association Standards of Care. [4]

How Does North Carolina Medicaid Cover Tresiba?

NC Medicaid covers Tresiba for beneficiaries with type 1 diabetes but does not cover it for type 2 diabetes as a preferred agent on the current preferred drug list. Type 2 patients on NC Medicaid are typically directed to insulin glargine (Lantus, Basaglar) or insulin detemir (Levemir) as first-line covered basal insulins. Prescribers can request a prior authorization for Tresiba in type 2 cases, though approval rates depend on documented intolerance or failure of covered alternatives.

NC Medicaid underwent its Tailored Care Management expansion in late 2022 and continues to evaluate its preferred drug list periodically. [5] The North Carolina Department of Health and Human Services publishes preferred drug list updates at least quarterly. Providers caring for type 2 Medicaid patients who need insulin degludec specifically should document prior therapeutic failures with glargine and detemir in detail before submitting a prior authorization. The authorization request should cite the clinical rationale supported by the ADA's 2024 Standards of Medical Care in Diabetes, which notes that basal insulin selection should account for hypoglycemia risk profile and dosing flexibility. [4]

For type 1 Medicaid patients, coverage is generally straightforward, though quantity limits may apply (typically a 30-day supply per fill). Patients enrolled in NC Medicaid Managed Care through a plan like Blue Cross NC or WellCare NC should verify their specific formulary, because managed care plan formularies sometimes differ from the base Medicaid preferred drug list. [6]

A 2021 Health Affairs analysis estimated that Medicaid programs nationwide covered basal insulin analogs at widely varying rates, with coverage gaps creating measurable disparities in A1C outcomes among low-income patients. [7] North Carolina's type 2 coverage gap for Tresiba fits that pattern.

Is Compounded Insulin Degludec Legal in North Carolina?

Compounded insulin degludec is legal in North Carolina when prepared by a licensed 503A compounding pharmacy operating under state Board of Pharmacy oversight and USP Chapter 797 sterile compounding standards. The key distinction is between 503A and 503B facilities: 503A pharmacies compound for individual patients with a valid prescription, while 503B outsourcing facilities produce larger batches. North Carolina's compounding pharmacies operate predominantly under the 503A framework for patient-specific insulin compounding.

The FDA does not approve compounded drug products for safety and efficacy the way it approves commercially manufactured drugs. [8] That means compounded insulin degludec has not undergone the same rigorous bioequivalence testing as branded Tresiba. Clinically, this matters because insulin potency and sterility standards must meet USP 797 requirements, but unit-to-unit concentration consistency can vary slightly between batches at smaller 503A pharmacies. [9]

The cost advantage of compounded insulin degludec can be substantial. In North Carolina, some 503A pharmacies offer compounded basal insulin at effectively $0 out-of-pocket when paired with certain telehealth platforms, compared with $35 per month cash-pay for branded Tresiba and $510 list. Patients considering this route should ask the pharmacy for its USP 797 inspection date and the most recent quality-control documentation, and they should discuss the switch with their prescribing clinician before changing insulin formulations. [8]

North Carolina's Board of Pharmacy maintains a public license verification database. Verifying that a pharmacy holds an active NC compounding license before filling an insulin prescription there takes less than two minutes online. [10] Any pharmacy that mails compounded insulin into North Carolina from another state must also hold an NC non-resident pharmacy license.

Which Insurance Plans Cover Tresiba in North Carolina?

Coverage depends on whether a plan is fully insured under state law or self-insured under ERISA. Fully insured commercial plans sold in North Carolina are subject to the state's insurance mandates, while self-insured employer plans are governed by federal ERISA rules and opt in or out of state formulary mandates independently.

Among the largest NC commercial insurers, Blue Cross NC includes Tresiba on its formularies at varying tier placements. Tier 3 placement is common, which means higher cost-sharing than generic or preferred brand alternatives. Aetna, Cigna, and UnitedHealthcare plans available in NC have placed Tresiba on specialty or non-preferred brand tiers in recent formulary cycles, pushing copays to $80 to $150 per month before manufacturer savings cards are applied. [11]

The ADA's 2024 Standards of Medical Care in Diabetes states directly: "Insulin access and affordability remain significant barriers to optimal diabetes management, and clinicians should proactively identify cost-reduction strategies for every patient." [4] That framing supports prescribers in documenting medical necessity when requesting formulary exceptions for Tresiba over a covered alternative.

NC marketplace (ACA exchange) plans sold through healthcare.gov follow standard formulary tiers set by each carrier. Premium tax credits can reduce monthly premiums, but drug cost-sharing is set at the plan level. Verifying Tresiba's tier before selecting a marketplace plan during open enrollment is straightforward using the plan's online formulary tool. [12] Patients who switch plans mid-year due to a qualifying life event should check whether the new plan requires a new prior authorization for an insulin they were already stabilized on.

For Medicare beneficiaries in North Carolina, Tresiba falls under Part D. Medicare Part D plans are required under 42 CFR 423.120 to cover at least one long-acting basal insulin analog. Tresiba appears on some NC Part D formularies but not all. The Medicare Plan Finder at medicare.gov allows patients to enter their exact prescriptions and compare monthly drug costs across all Part D plans available in their NC county. [13]

How Does the Novo Nordisk Savings Card Work in North Carolina?

Novo Nordisk operates two primary savings programs for Tresiba in the United States, including North Carolina: the Tresiba savings card for commercially insured patients and the My$99Insulin program for uninsured patients.

The savings card reduces out-of-pocket cost to as low as $10 per fill for eligible commercially insured patients. Eligibility excludes patients covered by any federal program, including Medicare, Medicaid, TRICARE, and the VA. North Carolina residents with employer-sponsored insurance or ACA marketplace insurance are generally eligible. The card is activated at NovoCare.com and can be used at most NC retail pharmacies. [14]

The My$99Insulin program caps monthly insulin costs at $99 per person for uninsured or underinsured patients in the United States, including North Carolina. Under this program, a patient can obtain up to three boxes of Novo Nordisk insulin (including Tresiba) per month at $99 total. [14] For a patient whose full monthly Tresiba supply fits in one or two boxes, that is a meaningful reduction from the $510 list price.

The table below summarizes the four primary cost pathways for Tresiba in North Carolina in 2026, arranged by estimated monthly out-of-pocket cost from lowest to highest:

| Pathway | Estimated Monthly OOP | Key Eligibility Limit | |---|---|---| | 503A compounded insulin degludec | $0 (via select telehealth platforms) | Valid NC prescription required; no federal insurance | | GoodRx or NeedyMeds discount coupon | ~$35 | Cash-pay only; cannot combine with insurance | | Novo Nordisk savings card | $10 per fill (commercially insured) | No federal program coverage | | My$99Insulin (uninsured) | $99/month cap | No insurance coverage of any Novo Nordisk insulin | | NC Medicaid (type 1 only) | $0 to $3 copay | Type 1 diagnosis; NC Medicaid enrollment | | Insurance (tier 3 commercial) | $80 to $150 before card | Plan-specific; prior auth may apply |

Patients should review current program terms directly at NovoCare.com because program details change annually. [14]

Can I Get Tresiba via Telehealth in North Carolina?

Yes. North Carolina permits telehealth prescribing of Tresiba, and the state does not require an in-person visit before a prescriber can issue a prescription for a non-controlled substance like insulin degludec. [15] This matters practically because HealthRX and similar telehealth platforms can evaluate a patient's diabetes management, review prior lab work, and issue a Tresiba prescription without the patient traveling to a clinic, which is particularly relevant for patients in rural NC counties with limited endocrinology access.

The North Carolina Medical Board's telemedicine policy requires that a valid patient-provider relationship be established and that the standard of care not be compromised by the telehealth modality. [15] For insulin prescribing, this typically means the provider reviews a recent A1C (within 90 days is common practice), current blood glucose logs, and any relevant comorbidities before prescribing or adjusting a basal insulin dose.

DEVOTE, a cardiovascular outcomes trial published in the New England Journal of Medicine in 2017 (N=7,637), found that insulin degludec was non-inferior to insulin glargine U-100 for major adverse cardiovascular events (MACE) and was associated with a 40% lower rate of severe hypoglycemia (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001). [2] That hypoglycemia safety advantage is clinically relevant when a telehealth provider is evaluating basal insulin selection for a patient without frequent in-office glucose monitoring.

Telehealth prescribing does not change the pharmacy dispensing process. A prescription issued by an NC-licensed provider via telehealth is legally equivalent to one written in an office. The patient fills it at any NC retail or mail-order pharmacy, or at a licensed compounding pharmacy if the prescription is written for a compounded formulation. [15]

What Are the Cheapest Ways to Get Tresiba in North Carolina?

The lowest cost pathway depends on insurance status. For uninsured NC residents, the options rank as follows.

Compounded insulin degludec through a licensed 503A pharmacy paired with a telehealth prescription represents the lowest cash outlay, sometimes $0 per month on certain platforms, though patients must accept that compounded insulin has not undergone FDA bioequivalence review. [8] NeedyMeds maintains a state-specific listing of patient assistance programs and compounding pharmacies. [3]

For patients who want branded Tresiba, GoodRx or RxSaver discount coupons at NC pharmacies bring the price to approximately $35 per month. These coupons cannot be combined with insurance benefits; the patient pays cash and submits the coupon at the pharmacy counter. [3]

Novo Nordisk's My$99Insulin program is the right fit for uninsured patients who want branded Tresiba and prefer a manufacturer-backed source. The $99 per month cap is higher than the $35 GoodRx price for a standard supply, so GoodRx is the better deal for most single-vial monthly supplies of Tresiba. My$99Insulin becomes advantageous when a patient needs more than one box per month. [14]

The Insulin Help for North Carolinians program through the NC Community Health Center Association may also provide insulin assistance to qualifying low-income patients. Eligibility thresholds and available insulin types vary by center. The Health Resources and Services Administration (HRSA) maintains a federally qualified health center (FQHC) finder for NC patients. [16]

Patient assistance programs (PAPs) are Novo Nordisk's most generous offering for very low-income uninsured patients. The NovoCare Patient Assistance Program provides free insulin to patients who meet income criteria (generally at or below 400% of the federal poverty level) and lack any drug coverage. Applications require income verification and a prescriber signature. [14]

A 2022 CDC report noted that approximately 8.4% of North Carolina adults had diagnosed diabetes, translating to over 700,000 people statewide, and that cost-related insulin underuse was reported by roughly one in four insulin-using adults nationally. [17] Programs like those above exist specifically to address that gap, but they require active enrollment, so the burden falls on patients and providers to pursue them.

How Does Tresiba Compare to Other Basal Insulins on Cost and Efficacy in NC?

Insulin glargine (Lantus, generic glargine, or biosimilar Semglee) is the most common covered alternative to Tresiba on NC Medicaid and many commercial formularies. Generic insulin glargine U-100 is available at some NC pharmacies for under $25 per month cash-pay, making it less expensive than Tresiba at the GoodRx price point. [3]

Efficacy differences between insulin degludec and insulin glargine U-100 are modest in head-to-head data. The SWITCH 2 trial (N=721, type 2 diabetes) found that switching from glargine U-100 to degludec reduced the rate of overall symptomatic hypoglycemia by 30% (rate ratio 0.70; 95% CI 0.61 to 0.80) without sacrificing glycemic control as measured by A1C. [18] The DEVOTE trial similarly showed degludec's hypoglycemia advantage over glargine in a high-cardiovascular-risk population. [2]

For a type 1 patient with recurrent nocturnal hypoglycemia on glargine, the hypoglycemia reduction data support a clinical case for switching to Tresiba, and that case should be documented in the prior authorization request when NC Medicaid or a commercial insurer is involved. The ADA 2024 Standards note that "patient-specific factors including hypoglycemia risk, injection burden, and cost should guide insulin selection." [4]

Insulin detemir (Levemir) is another covered NC Medicaid alternative. It has a shorter duration of action than degludec and often requires twice-daily dosing in type 1 patients, which increases injection burden without a clear cost offset for patients who need reliable 24-hour basal coverage. [19]

Biosimilar insulin glargine (Semglee, FDA-approved July 2021 as the first interchangeable insulin biosimilar in the U.S.) costs substantially less than Tresiba and is available at NC pharmacies. [20] For type 2 patients on NC Medicaid who cannot obtain a Tresiba prior authorization, Semglee represents a clinically appropriate covered alternative with lower cost burden.

What Should NC Patients Tell Their Provider Before Starting Tresiba?

Before a provider in North Carolina prescribes Tresiba, a brief but complete medication history speeds the process and reduces the chance of dose errors at transition. Patients should be ready to share the following.

Current basal insulin name, dose in units, and frequency. If transitioning from once-daily glargine U-100, the starting degludec dose is typically unit-for-unit. If transitioning from twice-daily detemir, the FDA label recommends starting degludec at 80% of the total daily detemir dose. [1]

Recent A1C and fasting glucose values. Telehealth providers reviewing these data remotely need lab results dated within 90 days to make safe dose decisions. [15]

Any episodes of severe hypoglycemia in the prior 12 months. Given DEVOTE's finding that degludec reduced severe hypoglycemia by 40% compared with glargine U-100, a history of severe lows strengthens the clinical rationale for degludec specifically. [2]

Insurance card details and pharmacy preference. Providing these at the time of the telehealth visit lets the provider send the prescription to the right pharmacy immediately and also allows the provider to discuss savings card eligibility in real time.

Renal function. Insulin requirements may decrease with worsening chronic kidney disease, and while degludec does not require dose adjustment for renal impairment per the FDA label, closer glucose monitoring is recommended. [1] The National Kidney Foundation provides guidance on diabetes management in CKD that is relevant for the many NC patients who have both conditions. [21]

Monitoring and Safety Considerations for Tresiba in NC

Insulin degludec carries a class-level black box warning for hypoglycemia, which is the most common adverse effect of all insulin products. [1] Patients starting Tresiba should have a glucagon emergency kit prescribed at the same time, particularly those with a prior severe hypoglycemia event. The FDA approved intranasal glucagon (Baqsimi) in 2019 as a needle-free option that many NC pharmacies stock. [22]

Blood glucose monitoring frequency should be established at the time of prescription. For patients without continuous glucose monitors (CGM), a minimum of fasting morning fingerstick glucose daily is standard practice during dose titration. The ADA recommends CGM for all adults with type 1 diabetes and for type 2 patients using insulin. [4]

The flexible dosing window of Tresiba (any time of day, with at least 8 hours between consecutive doses) reduces the risk of missed doses due to schedule changes, a practical advantage confirmed in a 2016 crossover pharmacokinetic study published in Diabetes Care. [23] Patients who travel frequently across time zones or work rotating shifts may find this flexibility clinically meaningful.

Drug interactions relevant to NC prescribers include thiazolidinediones (pioglitazone), which may cause fluid retention and worsen heart failure when combined with insulin, and SGLT-2 inhibitors, which reduce insulin requirements and increase diabetic ketoacidosis risk if insulin doses are not adjusted downward at initiation. [1] The ADA 2024 Standards specifically address insulin-SGLT-2 combinations for type 1 patients. [4]

North Carolina has 95 counties. Patients in rural counties (particularly in the Mountain and Coastal Plain regions) may face limited pharmacy hours, which affects insulin storage and pickup logistics. Tresiba pens can be stored at room temperature (below 86 degrees Fahrenheit) for up to 56 days after first use, longer than glargine U-100's 28-day room-temperature window, which is a meaningful practical advantage for patients with unreliable refrigeration access. [1]